NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Purchases 1,260 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper acquired 1,260 shares of the business’s stock in a transaction dated Wednesday, June 25th. The shares were acquired at an average price of $18.26 per share, for a total transaction of $23,007.60. Following the acquisition, the director now directly owns 3,026,133 shares in the company, valued at $55,257,188.58. This represents a 0.04% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

NewAmsterdam Pharma Trading Up 0.7%

Shares of NAMS stock opened at $18.45 on Friday. The firm’s fifty day moving average price is $18.68 and its two-hundred day moving average price is $20.80. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $27.29. The firm has a market capitalization of $2.07 billion, a P/E ratio of -9.81 and a beta of -0.03.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative net margin of 397.45% and a negative return on equity of 37.34%. The company had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. As a group, equities research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Keybank National Association OH bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $257,000. Swiss National Bank increased its holdings in NewAmsterdam Pharma by 105.1% during the fourth quarter. Swiss National Bank now owns 72,000 shares of the company’s stock worth $1,850,000 after buying an additional 36,900 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in NewAmsterdam Pharma during the fourth quarter worth $276,000. DCF Advisers LLC lifted its stake in NewAmsterdam Pharma by 162.9% in the fourth quarter. DCF Advisers LLC now owns 89,400 shares of the company’s stock valued at $2,298,000 after acquiring an additional 55,400 shares during the last quarter. Finally, American Century Companies Inc. acquired a new stake in NewAmsterdam Pharma in the fourth quarter valued at $8,907,000. 89.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on NAMS shares. Citigroup initiated coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a “buy” rating and a $42.00 target price on the stock. Stifel Nicolaus started coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 10th. They set a “buy” rating and a $44.00 price objective for the company. Wall Street Zen cut shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, June 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Finally, Cantor Fitzgerald initiated coverage on NewAmsterdam Pharma in a research note on Wednesday, June 4th. They issued an “overweight” rating and a $42.00 price target on the stock. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.89.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.